fiduxosin has been researched along with riluzole in 1 studies
| Studies (fiduxosin) | Trials (fiduxosin) | Recent Studies (post-2010) (fiduxosin) | Studies (riluzole) | Trials (riluzole) | Recent Studies (post-2010) (riluzole) |
|---|---|---|---|---|---|
| 14 | 3 | 5 | 1,244 | 153 | 572 |
| Protein | Taxonomy | fiduxosin (IC50) | riluzole (IC50) |
|---|---|---|---|
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | 4.73 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 10 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.733 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.733 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fiduxosin and riluzole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |